Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | CDK11B | P21127 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336426 | 0.89 | PDGFRB (0.47) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL627301 | 0.89 | PDGFRB (0.46) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12348882 | 0.87 | PDGFRB (0.54) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336509 | 0.86 | PDGFRB (0.54) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949292 | 0.84 | PDGFRB (0.50) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336261 | 0.84 | PDGFRB (0.55) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949515 | 0.84 | PDGFRB (0.57) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336421 | 0.83 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14952389 | 0.83 | PDGFRB (0.57) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL626906 | 0.82 | PDGFRB (0.54) | PDGFRBKITPDGFRACDK11BFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.